IDEAYA Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $218.7M | $7.0M | $23.4M | $50.9M | $27.9M |
| Research and development | $314.7M | $294.7M | $129.5M | $89.5M | $58.2M |
| Operating expenses | $378.0M | $334.0M | $157.8M | $113.4M | $78.2M |
| Operating income | -$159.3M | -$327.0M | -$134.4M | -$62.5M | -$50.3M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$113.7M | -$274.5M | -$113.0M | -$58.7M | -$49.8M |
| Balance Sheet | |||||
| Cash and equivalents | $112.8M | $84.4M | $157.0M | $68.6M | $92.0M |
| Current assets | $666.7M | $689.7M | $532.6M | $370.5M | $251.0M |
| Total assets | $1.1B | $1.1B | $649.3M | $388.0M | $381.3M |
| Current liabilities | $58.8M | $46.1M | $27.1M | $31.7M | $45.2M |
| Total liabilities | $86.4M | $64.9M | $28.2M | $38.5M | $79.8M |
| Stockholders' equity | $1.0B | $1.1B | $621.1M | $349.5M | $301.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$71.1M | -$247.6M | -$115.2M | -$87.2M | -$55.8M |
| Depreciation and amortization | $2.7M | $2.4M | $2.5M | $2.1M | $1.7M |
| Stock-based compensation | $46.1M | $34.7M | $18.5M | $11.6M | $8.2M |
| Capital expenditure | $2.4M | $3.9M | $2.4M | $3.4M | $2.6M |
| Free cash flow | -$73.5M | -$251.4M | -$117.6M | -$90.6M | -$58.4M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 87.9M · Free float 91.5%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.